Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous pembrolizumab with platinum doublet chemotherapy in first-line metastatic squamous or nonsquamous non-small cell lung cancer
2023-508308-40-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1 and Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508308-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508308-40-00.